Purdue Pharma L.P. Awards Grant for Investigator-initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection
The Supreme Court on Thursday blocked, for now, a multi-billion-dollar bankruptcy settlement by Purdue Pharma that would protect its Sackler family owners from civil lawsuits related to the opioid crisis.
NEW YORK, Aug 4 (Reuters) - Oxycontin maker Purdue Pharma on Friday asked the U.S. Supreme Court to reject the U.S. Department of Justice's request to delay its multi-billion-dollar bankruptcy settlement resolving thousands of lawsuits against it over the opioid epidemic.
NEW YORK, July 28 (Reuters) - The U.S. Department of Justice on Friday asked the U.S. Supreme Court to stop Purdue Pharma from proceeding with a bankruptcy settlement that protects its Sackler family owners from lawsuits.
NEW YORK (Reuters) - OxyContin maker Purdue Pharma may proceed with a bankruptcy settlement that protects its Sackler family owners from lawsuits, despite a potential U.S. Supreme Court appeal in the case, a U.S. court ruled on Tuesday.
After years of litigation, a United States appeals court has endorsed Purdue Pharma’s $6 billion opioid settlement and awarded legal protections for its former owners, the billionaire Sackler family.
In a previous installment, we described an alternative cell treatment which relies on synNotch receptors. These synthetic receptors react to a specific input and produce a desired cell response. This modular design promises greater therapeutic flexibility than its more well-established counterpart, CAR T therapy. The design is further improved when integrated with a universal adaptor called SNAPtag. Here, we describe how researchers at the University of Pittsburgh developed this synNotch-adaptor duo and how it works.
STAMFORD, Conn.--(BUSINESS WIRE)--Today, the U.S. Court of Appeals for the Second Circuit ruled in favor of Purdue Pharma’s chapter 11 Plan of Reorganization (the “Plan”), affirming the bankruptcy court’s September 2021 confirmation order.
A federal bankruptcy judge on Tuesday approved Purdue Pharma’s $397 million sale of its consumer health unit to a subsidiary of Arcadia Consumer Healthcare.
NEW YORK, May 23 (Reuters) - Bankrupt Purdue Pharma received a U.S. judge's permission on Tuesday to sell its consumer health business for $397 million to a subsidiary of Arcadia Consumer Healthcare.